Similar articles for PMID: 24934864

Year	Number of Results
1970	2
1977	1
1978	1
1983	2
1984	1
1988	1
1993	3
1994	1
1995	2
1996	2
1997	4
1998	2
1999	2
2000	1
2001	3
2002	2
2003	4
2004	5
2005	6
2006	5
2007	6
2008	3
2009	5
2010	4
2011	1
2012	2
2013	6
2014	10
2015	6
2016	4
2017	6
2018	4
2019	7
2020	3
2021	11
2022	5
2023	2
2024	0

1

Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.

Borghorst S, Hempel G, Poppenborg S, Franke D, König T, Baumgart J. Borghorst S, et al. Cancer Chemother Pharmacol. 2014 Aug;74(2):367-78. doi: 10.1007/s00280-014-2506-9. Epub 2014 Jun 17. Cancer Chemother Pharmacol. 2014. PMID: 24934864

2

Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.

Poppenborg SM, Wittmann J, Walther W, Brandenburg G, Krähmer R, Baumgart J, Leenders F. Poppenborg SM, et al. Eur J Pharm Sci. 2016 Aug 25;91:122-30. doi: 10.1016/j.ejps.2016.06.007. Epub 2016 Jun 10. Eur J Pharm Sci. 2016. PMID: 27292820

3

Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

Heo YA, Syed YY, Keam SJ. Heo YA, et al. Drugs. 2019 May;79(7):767-777. doi: 10.1007/s40265-019-01120-1. Drugs. 2019. PMID: 31030380 Free PMC article. Review.

4

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar^® in Children with Acute Lymphoblastic Leukemia.

Würthwein G, Lanvers-Kaminsky C, Hempel G, Gastine S, Möricke A, Schrappe M, Karlsson MO, Boos J. Würthwein G, et al. Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):955-963. doi: 10.1007/s13318-017-0410-5. Eur J Drug Metab Pharmacokinet. 2017. PMID: 28349335 Clinical Trial.

5

FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).

Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. Dinndorf PA, et al. Oncologist. 2007 Aug;12(8):991-8. doi: 10.1634/theoncologist.12-8-991. Oncologist. 2007. PMID: 17766659 Free article. Clinical Trial.

6

Population pharmacokinetics of native Escherichia coli asparaginase.

Borghorst S, Pieters R, Kuehnel HJ, Boos J, Hempel G. Borghorst S, et al. Pediatr Hematol Oncol. 2012 Mar;29(2):154-65. doi: 10.3109/08880018.2011.627978. Pediatr Hematol Oncol. 2012. PMID: 22376019 Clinical Trial.

7

Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.

Tram Henriksen L, Gottschalk Højfeldt S, Schmiegelow K, Frandsen TL, Skov Wehner P, Schrøder H, Klug Albertsen B; Nordic Society of Pediatric Hematology and Oncology, NOPHO Group. Tram Henriksen L, et al. Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26686. Epub 2017 Jun 29. Pediatr Blood Cancer. 2017. PMID: 28660740 Clinical Trial.

8

Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.

Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G, Boos J. Vieira Pinheiro JP, et al. Pediatr Blood Cancer. 2006 Jan;46(1):18-25. doi: 10.1002/pbc.20406. Pediatr Blood Cancer. 2006. PMID: 15929133 Clinical Trial.

9

Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.

Müller HJ, Löning L, Horn A, Schwabe D, Gunkel M, Schrappe M, von Schütz V, Henze G, Casimiro da Palma J, Ritter J, Pinheiro JP, Winkelhorst M, Boos J. Müller HJ, et al. Br J Haematol. 2000 Aug;110(2):379-84. doi: 10.1046/j.1365-2141.2000.02187.x. Br J Haematol. 2000. PMID: 10971395 Free article.

10

PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols.

Müller HJ, Beier R, da Palma JC, Lanvers C, Ahlke E, von Schütz V, Gunkel M, Horn A, Schrappe M, Henze G, Kranz K, Boos J. Müller HJ, et al. Cancer Chemother Pharmacol. 2002 Feb;49(2):149-54. doi: 10.1007/s00280-001-0391-5. Epub 2001 Nov 16. Cancer Chemother Pharmacol. 2002. PMID: 11862429

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

122 results

Results by year